Vivani Medical Inc (VANI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.04-2.80%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · VANI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 357.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
VANI — litigation filed
Dated 2026-10-30
shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing. Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than historical fact, and may include statements relating to goals, plans and objectives related to…
Why it matters: The results test whether NPM-139 can move toward a Phase 2 dose study in 2027.
Watch forBy November 30, Vivani reports SLIM-1 results. The implant group shows acceptable safety and drug levels.
Also watch forVivani reports a serious safety issue or poor drug levels. Results are delayed past November 2026.
Why it matters: Closing would make Cortigent a separate public company. It would also lower Vivani's direct costs for Cortigent.
Supportive ifVivani confirms the merger closed. Cortigent Holdings starts trading as CRGT.
Worry ifThe merger is terminated, misses its closing terms, or CRGT does not begin trading.
Why it matters: A filing and trial start would show progress beyond the small Phase 1 study.
Supportive ifVivani files the NPM-139 IND and starts a Phase 2 dose study in 2027.
Worry ifThe IND or Phase 2 start slips past 2027, or Vivani says it will not proceed.
Why it matters: Vivani is loss-making, and its stated cash runway reaches only the first half of 2027.
Worry ifCash falls below $15 million by the next two quarterly reports, or Vivani says its runway ends before mid-2027.
Less concerning ifCash remains at or above $20 million and management keeps its runway through the first half of 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$214 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $644 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,869 loss on $10,000 · 38.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.